Chronic GVHD and Management of its Sequelae

慢性 GVHD 及其后遗症的处理

基本信息

批准号：
10679975
负责人：
SUNG WON CHOI
金额：
$ 2.2万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-04-19 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10679975
关键词：
Administrator Adolescent and Young Adult Adult Affect Allogenic American Area Award Basic Science Biometry Canada Cell Therapy Cellular biology Child Child Care Childhood Classification Clinical Clinical Research Clinical Trials Code Collaborations Dedications Development Diagnosis Donor Selection Education Ensure Ethics Etiology Evaluation Family Functional disorder Future Geographic Locations Grant Health Health Professional Healthcare Heart Diseases Hematological Disease Hematology Immunologics Immunology Individual Institution International Knowledge Laboratory Technicians Lead Leadership Letters Life Expectancy Long-Term Survivors Lung Lung diseases Malignant - descriptor Medical Medical Students Mentors Mentorship Midwestern United States Minority Groups Mission Molecular Biology Monitor Morbidity - disease rate National Cancer Institute National Heart, Lung, and Blood Institute Non-Malignant Nurse Practitioners Nurses Oncology Oral Organ Patients Pediatric Hematology Persons Physician Assistants Physicians Prevention Quality of life Research Research Personnel Science Scientific Advances and Accomplishments Scientist Severities Site Societies Specialist Standardization Testing Texas Training Translational Research Transplant Recipients Travel Underrepresented Minority Underrepresented Populations United States National Institutes of Health Vagina anticancer research chronic graft versus host disease clinical investigation curative treatments follow-up forging graduate student hematopoietic cell transplantation improved innovation interest meetings member mortality novel strategies novel therapeutics posters professor programs stem stem cell biology success survivorship symposium transplantation therapy

项目摘要

PROJECT SUMMARY We propose to organize and conduct the Tenth (10th) Annual Pediatric Transplant and Cellular Therapy Consortium (PTCTC) Meeting at the Fort Worth Convention Center in Fort Worth, TX, on May 09, 2023. A unique aspect of the Annual PTCTC Educational Meeting is that it is jointly held with the international American Society of Pediatric Hematology Oncology Conference (May 10–13, 2023) and includes a Combined Plenary Session, bringing pediatric hematology oncology professionals together from around the world. Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for childhood hematological conditions. Advances in basic, translational, and clinical research have significantly increased the number of long-term survivors. The remarkable success is owed in part to the presentation, dissemination, and sharing of new knowledge at annual meetings. However, none is solely dedicated to pediatric HCT. A significant problem in the field is chronic graft- versus-host disease (cGVHD). Despite cure, cGVHD is the leading cause of late morbidity and mortality. With their longer life expectancy, a critical need exists to understand the etiology, prevention, development, and diagnosis, and systematically evaluate and monitor cGVHD in children. The 10th Annual PTCTC Educational Meeting will convene clinicians and scientists who will present on the immunologic mechanisms leading to the initiation and development of cGVHD. This will provide a platform that stimulates how to implement systematic cGVHD assessments in a busy clinical setting. In doing so, innovative clinical strategies can be developed and tested across multi-site collaborations and networks, including novel therapeutics for pediatric-specific cGVHD clinical trials. This 1-day program will invigorate the field of pediatric HCT. The primary objectives include I) identify optimal donor selection strategies that can be standardized and implemented irrespective of the treating institution; II) systematically conduct comprehensive cGVHD assessments that accurately classify individual organ and global organ severity at baseline and in follow-up irrespective of the evaluator; III) to review the ‘state of the science’ in cGVHD immunology and management of affected organ dysfunctions (e.g., pulmonary, ocular, vaginal); IV) to enhance the understanding of wellness, thereby maximizing long-term quality-of-life and survivorship of pediatric HCT patients; and V) to promote networking and collaboration of research and clinical24 trials involving pediatric HCT patients. The results of the 10th Annual PTCTC Educational Meeting will likely enhance our understanding of the basic, translational, and clinical state of the scientific research in pediatric- specific cGVHD, which will provide an opportunity and platform to engage young and senior clinicians and scientists to develop collaborative research. The Organizing Committee will make every effort to enhance diversity by increasing individuals from diverse backgrounds, including those from underrepresented groups. Participation of trainees and underrepresented minorities is especially encouraged through travel awards.

项目摘要我们建议组织和进行第十（第10）年的小儿移植和细胞治疗 2023年5月9日年度PTCTC教育会议的各个方面是与国际美国社会共同举行小儿血液肿瘤学会议（5月10日至13日，2023年），包括一个全体会议，将小儿血液肿瘤学专业人员聚集在一起。同种异体造血细胞移植（HCT）是针对儿童血液学疾病的潜在治疗疗法。进步基本，翻译和临床研究已显着增加了长期幸存者的数量。在年度的演讲，传播和共享新知识的部分取得了巨大的成功。会议。但是，没有一个仅专用于小儿HCT。该领域的一个重大问题是慢性移植与宿主病（CGVHD）。尽管治愈了，但CGVHD是晚期发病率和死亡率的主要原因。和他们的预期寿命更长，存在关键需求，以了解病因，预防，发展和诊断，并系统地评估和监视儿童中的CGVHD。第10届PTCTC教育会议将方便的临床医生和科学家，他们将以免疫机制的形式出现 CGVHD的启动和开发。这将提供一个刺激如何实施系统的平台在繁忙的临床环境中的CGVHD评估。这样，可以制定创新的临床策略，并跨多站点合作和网络测试，包括针对小儿特异性CGVHD的新疗法临床试验。这个为期1天的计划将激发小儿HCT的领域。主要对象包括i）确定最佳的捐助者选择策略，无论治疗方法如何机构; ii）系统地进行全面的CGVHD评估，以准确对个体进行分类基线和随访的器官和全球器官严重程度如何评估； iii）审查“状态” 科学在CGVHD免疫学和受影响器官功能障碍的管理（例如肺，眼，，阴道）; iv）增强对健康的理解，从而最大化长期生活质量和小儿HCT患者的生存； v）促进研究和临床的网络和协作24 涉及小儿HCT患者的试验。第十届PTCTC教育会议的结果可能会增进我们对小儿科学研究的基本，翻译和临床状态的理解特定的CGVHD，它将提供机会和平台，以吸引年轻和高级临床医生和科学家开发合作研究。组织委员会将尽一切努力加强通过增加潜水员背景的个人，包括来自代表性不足的群体的多样性。通过旅行奖特别鼓励学员和代表性不足的少数民族的参与。